Sharechat Logo

TruScreen - Commercial Breakthrough in Saudi Arabia

Monday 18th September 2023

Text too small?

TruScreen Group Limited (NZX/ASX:TRU) is pleased to report that the Dr Sulaiman Al-Habib Medical Group, has installed the first tranche of four TruScreen devices for commercial use, for the screening of cervical cancer in Saudi Arabia.

 

Dr Sulaiman Al-Habib Medical Group (DSAMG) is the largest private hospital network in the Middle East. The adoption of TruScreen’s screening technology by DSAMG private hospitals will be important reference sites for further market access in neighbouring Middle Eastern nations.

 

This installation follows from the previously announced successful completion of the clinical evaluation by DSAMG network, followed by a successful tender by BettaLife Trading FZC (BettaLife) (Truescreen’s distributor in the Middle East).

 

The excellent clinical results of the evaluation were announced previously: see link

 

https://www.nzx.com/announcements/408275

 

TruScreen’s CEO, Dr Beata Edling said:

 

“I am very pleased that the Dr Sulaiman Al-Habib Medical Group have approved and will use TruScreen technology to advance the screening for cervical cancer in their hospital network.

We congratulate BettaLife, our partner in Saudi Arabia, on reaching this important milestone which will support the expansion of the TruScreen operations in the Middle East.”

 

This announcement has been approved by the Board.

 

Ends

Commercial Breakthrough in Saudi Arabia - Commences use of TruScreen Technology



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors
December 19th Morning Report
RAD - Radius Care Announces On-market Share Buyback Programme
MCY - New wind farm propels MCY renewables commitment to $1b